Diagnostics World Article: Droplet Biosciences Turns Post-Op Waste Into Life-Saving Data

https://www.diagnosticsworldnews.com/news/2026/03/11/droplet-biosciences-turns-post-op-waste-into-life-saving-data By Allison Proffitt  March 11, 2026 | When surgeons remove a solid tumor, they place a small drain in the resulting cavity to draw off lymphatic fluid that collects there; whatever comes out is simply thrown away. But what is really being poured down the drain? That’s what Dr. Jose P. Zevallos, Chair of Otolaryngology at University of Pittsburgh Medical Center, asked. The resulting startup, Droplet Bioscience, founded in 2021, has built a Clinical Laboratory Improvements Amendments […]

Droplet Biosciences-Study Reveals Post-Surgical Lymph Fluid as a Powerful Source of ctDNA for Early Recurrence Detection in Head & Neck Cancer

CAMBRIDGE, Mass., Nov. 13, 2025 /PRNewswire/ — Droplet Biosciences, a company pioneering the use of lymphatic fluid for advanced clinical diagnostics, announces the online release of a peer-reviewed publication with results of a groundbreaking clinical study demonstrating that lymphatic fluid collected via surgical drains in patients after resection of HPV-independent head & neck squamous cell […]

Droplet Biosciences Accelerates Residual Cancer Detection with NVIDIA

Droplet reduces genomic analysis time using NVIDIA Parabricks, enabling rapid turnaround of test results https://www.prnewswire.com/news-releases/droplet-biosciences-accelerates-residual-cancer-detection-with-nvidia-302702708.html CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ — Droplet Biosciences, a diagnostics company pioneering lymph-based liquid biopsy testing, today announced that it is dramatically reducing genomic analysis time with NVIDIA AI infrastructure—improving test turnaround times and enabling more timely, informed patient care. Droplet’s LymphDetect™ test uses deep […]

A Liquid Biopsy for Local Recurrences

AACR shared four cutting-edge highlights from the AACR-AHNS conference (July 7-8, 2023), including Droplet Biosciences data presented by co-founder Dr. José Zevallos that shows lymph is superior to plasma at predicting local recurrences. August 3, 2023  Read the full article in Cancer Research Catalyst: The Official Blog of the American Association for Cancer Research: 

Droplet Biosciences Releases First Research Data, Demonstrates Lymph Liquid Biopsy‘s Ability to Predict Locoregional Recurrence

Montréal, QC, Canada – July 8, 2023 – Droplet Biosciences, a pioneer in harnessing the power of lymphatic fluid to provide earlier and more sensitive cancer diagnostics, released its initial research data this morning at AACR-AHNS Head and Neck Conference: Innovating through Basic, Clinical and Translational Research. The abstract Detection of minimal residual disease in post-surgical […]

Droplet Biosciences Announces Lymph Diagnostic Platform to Help Prevent Cancer Recurrence

With an $8 million seed investment led by The Engine, Droplet will develop a novel lymph liquid biopsy for earlier, more precise care following surgery.  https://www.businesswire.com/news/home/20230316005040/en/Droplet-Biosciences-Announces-Lymph-Diagnostic-Platform-to-Help-Prevent-Cancer-Recurrence CAMBRIDGE, MA – March 16, 2023 – Droplet Biosciences today announced an $8 million seed investment to establish proof of concept for the company’s technology. While the lymphatic system’s […]

Droplet Biosciences Targets Lymph Fluid in New Residual Cancer Detection Strategy

With an $8M seed investment led by The Engine, Droplet will develop a liquid biopsy test using lymphatic fluid rather than blood plasma as a source for detecting cancer-associated DNA alterations. March 16, 2023 Read the full article on GenomeWeb: https://www.genomeweb.com/cancer/droplet-biosciences-targets-lymph-fluid-new-residual-cancer-detection-strategy#.ZBMW5-zMKrc